Nachrichten zur GSK PLC Aktie

GSK Aktie: Specialty Medicines Segment wächst

Wien (www.aktiencheck.de) - GSK-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt die…

GSK upgrades long-term sales target; but Arexvys struggles are confirmed

GSK PLC (LSE:GSK, NYSE:GSK) has raised its long-term revenue forecast, now expecting sales to exceed £40 billion by 2031, up from…

FTSE 100 led higher by GSK; Gold trounces record on Trump trade spat

FTSE 100 gains 40 points GSK surges on update Gold hits record US$2,882 6.01pm: FTSE 100 heads for positive finish GSK PLC…

GSK plc (GSK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

…

GSK Aktie: Der Pharma-Riese will IDRx akquirieren

Kulmbach (www.aktiencheck.de) - GSK-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…

GSK swoops for US cancer specialist in $1.15bn deal

GSK PLC (LSE:GSK, NYSE:GSK) has announced plans to acquire the US biotech company IDRx for up to $1.15bn, including $1bn upfront,…

GSKs new shingles jab submitted for review by US regulator

GSK PLC (LSE:GSK, NYSE:GSK) has announced that the US Food and Drug Administration (FDA) is reviewing its new prefilled syringe version…

GSK swooping to buy US biotech IDRx for $1bn

UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business,…

GSK’s experimental cancer drug wins receives support from US regulator

GSK PLC (LSE:GSK, NYSE:GSK) has received a major boost for its experimental drug GSK5764227 (GSK’227), which targets a rare and aggressive…

GSK’s Nucala approved in China for treating nasal polyps

GSK PLCs (LSE:GSK, NYSE:GSK) Nucala (mepolizumab) has been approved in China to treat adults with chronic rhinosinusitis with nasal polyps (CRSwNP)…

GSK’s FIRST trial achieves progression-free survival milestone in advanced ovarian cancer

GSK PLC (LSE:GSK, NYSE:GSK) has announced that its phase III FIRST-ENGOT-OV44 trial met its primary goal, or endpoint. The study showed…

Top European Activist Investor Bluebell to Shutter Hedge Fund

Bluebell Capital Partners, the European activist investment firm, is shutting down its hedge fund after targeting high-profile companies from pharmaceutical…

GSK passes three significant milestones with new cancer drug given a double boost

GSK PLC (LSE:GSK, NYSE:GSK) has announced significant progress in its oncology pipeline, achieving three milestones. The European Medicines Agency (EMA)…

GSK says blood cancer drug shows dramatic survival gains in key trial

GSK PLC (LSE:GSK, NYSE:GSK) shares in New York rose Monday afternoon after it announced that its blood cancer drug Blenrep…

GSK extends vaccine partnership with Zhifei in China

GSK PLC (LSE:GSK, NYSE:GSK) has extended its partnership with Chongqing Zhifei Biological Products (Zhifei) to bring its shingles vaccine, Shingrix,…

GSK’s receives European Commission green light for liquid form of key vaccine

GSK PLC (LSE:GSK, NYSE:GSK) has received approval from the European Commission for a new, fully liquid version of its Menveo vaccine,…

GSK submits multiple myeloma treatment for approval to the US regulator

The US Food and Drug Administration (FDA) has accepted GSK PLC (LSE:GSK, NYSE:GSK)’s application to review the use of Blenrep…

GSK’s RSV vaccine gets greenlight in Japan

GSK PLC (LSE:GSK, NYSE:GSK) has announced that Japan’s Ministry of Health, Labour and Welfare has approved its RSV vaccine, Arexvy,…

GSK trial shows promising results for treatment of persistent itch in rare liver disease

GSK PLC (LSE:GSK, NYSE:GSK)has reported positive results from its phase III trial of linerixibat, a drug being tested to treat…

ANALYSE-FLASH: Deutsche Bank Research senkt GSK auf 'Hold' - Ziel 1350 Pence

FRANKFURT (dpa-AFX Broker) - Deutsche Bank Research hat GSK von "Buy" auf "Hold" abgestuft und…

Trump anti-vax health appointment wipes £7bn from AstraZeneca and GSK

Almost £7 billion was wiped from the combined market values of GSK PLC and AstraZeneca PLC on Friday after Donald Trump unveiled his…

GSK going nowhere while key vaccines struggle, says US bank

GSK PLC (LSE:GSK, NYSE:GSK) looks undervalued, but the problem is that there is nothing on the horizon to change that perception…

GSK Aktie: Story nicht wesentlich verändert

Wien (www.aktiencheck.de) - GSK-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), rät in…

GSK Aktie: Pipeline-Updates abwarten - Guggenheim senkt das Rating

New York (www.aktiencheck.de) - GSK-Aktienanalyse von Guggenheim Securities: Aktuelle Bewertung Guggenheim-Analyst, Seamus Fernandez, hat GSK plc (ISIN: GB00BN7SWP63, WKN: A3DMB5, Ticker-Symbol: GS71,…

Vergleich für Medikament Zantac überschattet Quartal beim Pharmakonzern GSK

LONDON (dpa-AFX) - Der Milliardenvergleich in den Rechtsstreitigkeiten rund um die Arznei Zantac in den USA…

GSK Inks Lupus Deal With Chinese Biotech for Up to $850 Million

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to…

GSK looking to move on from Zantac litigation

GSK PLC (LSE:GSK, NYSE:GSK) share price bump on settlement of most of its Zantac litigation claims has reversed recently on…

GSK Zantac settlement a clear win, say brokers

GSK PLC (LSE:GSK, NYSE:GSK) US$2.2 billion settlement for 93% of Zantac litigation cases is almost a best-case scenario short of no…

GSK: Vergleich in der Zantac-Sache in den USA - Aktiennews

Frankfurt (www.aktiencheck.de) - GSK: Vergleich in der Zantac-Sache in den USA - Aktiennews Die Aktien des britischen Pharmariesen GSK plc (GlaxoSmithKline)…

GSK Aktie: Das ist ein Paukenschlag!

Kulmbach (www.aktiencheck.de) - GSK-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…

GSK settles US Zantac lawsuit for $2.2bn

GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay up to $2.2 billion to settle around 80,000 US lawsuits concerning its heartburn…

GSK: Does RSV jab work too well?

GSK PLCs respiratory syncytial virus (RSV) vaccine, Arexvy, faces challenges that could impact its financial future, according to a report by…

Does GSKs RSV jab work too well?

GSK PLCs respiratory syncytial virus (RSV) vaccine, Arexvy, faces challenges that could impact its financial future, according to a report by…

Does GSKs RSV jab work too well?

GSK PLCs respiratory syncytial virus (RSV) vaccine, Arexvy, faces challenges that could impact its financial future, according to a report by…

GSK cancer drugs fast-tracked by Chinese

GSK PLC (LSE:GSK, NYSE:GSK) announced that its blood cancer drug Blenrep (belantamab mafodotin), in combination with two current treatments, has…

GSK enjoys success with mRNA flu vaccine trial

GSK PLC (LSE:GSK, NYSE:GSK) has been encouraged by the initial results of a seasonal flu vaccine using mRNA technology. Following…

GSK clouds blowing over suggests Berenberg

GSK PLC (LSE:GSK, NYSE:GSK) has been reiterated as a buy at broker Berenberg, which sees some of the ‘clouds of…

GSK herpes vaccine fails in clinical trial

Shares in GSK PLC (LSE:GSK, NYSE:GSK) fell over 1% after the drug maker said it would abandon further trials for…

GSK drug promotes ‘significant and clinically meaningful reduction’ in asthma symptoms

British pharmaceuticals giant GSK PLC (LSE:GSK, NYSE:GSK) has presented late-breaking data at the European Respiratory Society (ERS) International Congress,...…

GSK verdient operativ mehr und erhöht Jahresziele - Aktie dennoch im Minus

LONDON (dpa-AFX) - Beim Pharmakonzern GSK laufen die Geschäfte weiterhin rund. Für das Gesamtjahr hob…

Merz will europäische Pharmaindustrie stärken

DRESDEN (dpa-AFX) - Der CDU-Bundesvorsitzende Friedrich Merz will die Wettbewerbsfähigkeit der europäischen Pharmaindustrie stärken. Es brauche…

ANALYSE-FLASH: UBS senkt GSK auf 'Neutral' - Ziel runter auf 1580 Pence

ZÜRICH (dpa-AFX) - Die Schweizer Großbank UBS hat GSK von "Buy" auf "Neutral" abgestuft und…

Pharmahersteller GSK erhöht Gewinnziel für 2024

LONDON (dpa-AFX) - Der Pharmakonzern GSK ist besser als erwartet in das neue Jahr gestartet.…

ANALYSE-FLASH: Jefferies belässt GSK auf 'Buy' - Ziel 1950 Pence

NEW YORK (dpa-AFX Broker) - Das Analysehaus Jefferies hat die Einstufung für GSK auf "Buy"…

ROUNDUP: Pharmahersteller GSK will auch 2024 mehr verdienen - Aktie legt zu

LONDON (dpa-AFX) - Der Pharmakonzern GSK rechnet nach einem Ergebnis- und Umsatzplus im vergangenen Jahr…

Pharmahersteller GSK will auch 2024 mehr verdienen - optimistischer für Zukunft

LONDON (dpa-AFX) - Der Pharmakonzern GSK rechnet nach einem Ergebnis- und Umsatzplus im vergangenen Jahr…

ANALYSE-FLASH: Jefferies hebt GSK auf 'Buy' und Ziel auf 1900 Pence

NEW YORK (dpa-AFX) - Das Analysehaus Jefferies hat GSK von "Hold" auf "Buy" hochgestuft und…

ANALYSE-FLASH: Jefferies hebt GSK auf 'Buy' und Ziel auf 1900 Pence

NEW YORK (dpa-AFX) - Das Analysehaus Jefferies hat GSK von "Hold" auf "Buy" hochgestuft und…

ANALYSE-FLASH: Jefferies senkt Ziel für GSK auf 1550 Pence - 'Hold'

NEW YORK (dpa-AFX Broker) - Das Analysehaus Jefferies hat das Kursziel für GSK von 1650…

ANALYSE-FLASH: JPMorgan hebt Ziel für GSK auf 1400 Pence - 'Underweight'

NEW YORK (dpa-AFX Broker) - Die US-Bank JPMorgan hat das Kursziel für GSK nach Zahlen…